Serum Anti-Spike Antibodies Are Not Affected by Immunosuppressants in SARS-CoV-2 Vaccinations Given to Brazilian Patients with Inflammatory Bowel Disease.
| Autor: | Pereira, Magno Luís Costa, Moreira, Jessica Pronestino de Lima, Porto, Luís Cristóvão, Souza, Vania Maria Almeida de, Gonçalves, Beatriz Cunta, Sampaio, Amanda de Barros, Moutela, Matheus Figueiredo, Farha, Larissa dos Reis, Esberard, Bárbara Cathalá, Amorim, Renata Fernandes de, Souza, Heitor Siffert Pereira de, Carvalho, Ana Teresa Pugas |
|---|---|
| Předmět: |
STATISTICS
KRUSKAL-Wallis Test INFLAMMATORY bowel diseases SCIENTIFIC observation IMMUNIZATION COVID-19 vaccines SERUM CHEMILUMINESCENCE assay MULTIPLE regression analysis TERTIARY care CASE-control method BLOOD collection MANN Whitney U Test ANTIBODY formation IMMUNOASSAY COMPARATIVE studies MESSENGER RNA DESCRIPTIVE statistics STATISTICAL hypothesis testing VIRAL antibodies IMMUNOSUPPRESSIVE agents ANALYTICAL chemistry techniques DATA analysis software DATA analysis OUTPATIENT services in hospitals LONGITUDINAL method |
| Zdroj: | Healthcare (2227-9032); Oct2023, Vol. 11 Issue 20, p2767, 12p |
| Abstrakt: | This study aimed to evaluate humoral responses after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) of patients with inflammatory bowel disease (IBD). Patients with IBD enrolled in a tertiary outpatient unit were followed up between September 2021 and September 2022 via serial blood collection. Immunoglobulin G antibody titers against SARS-CoV-2 were measured before administration and 1 and 6 months after the administration of two doses of different vaccination regimens. The results were compared with those of a healthy control group obtained during the same period. The mean pre-vaccination antibody titers were 452.0 and 93.3 AU/mL in the IBD (n = 42) and control (n = 89) groups, respectively. After two doses of the vaccine, the titers significantly increased in both groups (IBD, 8568.0 AU/mL; control, 7471.0 AU/mL; p < 0.001). One month after the second dose, no significant differences were observed between the two groups (p = 0.955). Significant differences between vaccination schemes in the IBD group were observed, with higher titers in those who received Pfizer, younger patients (p < 0.005), and those with a previous coronavirus disease 2019 (COVID-19) infection (p < 0.012). The use of immunosuppressants and immunobiologicals did not affect the overall humoral response to COVID-19 vaccine in patients with IBD, but specific vaccine regimens, age, and previous coronavirus infection significantly did. This study reinforces the positive impact of booster doses and the safety of SARS-CoV-2 vaccination. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|